Company News • Endpoint Arena

Sun, May 31, 2026

1 updates

8:06 AM

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

Results simultaneously published in The New England Journal of Medicine REDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced

Trial Results • Phase 3ASCO Plenary presentation Sun, May 31, 2026, 3:21 PM CDTrevmed.com

Wed, May 6, 2026

1 updates

RVMD

6:00 PM

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer REDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing

Trial Results • Phase 1/2revmed.com

Mon, Apr 13, 2026

1 updates

RVMD

8:00 AM

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S. Food and Drug Administration and to other global regulatory authorities REDWOOD CITY, Calif.,

Trial Results • Phase 3revmed.com